On this page

Neomycin and Polymyxin B Sulfates and Hydrocortisone

neomycin sulfate, polymyxin b sulfate and hydrocortisone · Solution

Prescription ANDA TE AT Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Neomycin and Polymyxin B Sulfates and Hydrocortisone
Generic name
neomycin sulfate, polymyxin b sulfate and hydrocortisone
Dosage form
Solution
Route
Auricular (Otic)
Marketing category
ANDA · ANDA
Labeler
Proficient Rx LP
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
3
NDC product codes
2
Packages
2
Data completeness
76% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Hydrocortisone 10 mg/mL 604449 View
Neomycin Sulfate 3.5 mg/mL 204602 View
Polymyxin B Sulfate 10000 [iU]/mL 204602 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Solution
Route of administration
Auricular (Otic)
Presentations
4

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Aminoglycoside Antibacterial [EPC] EPC All 66 members
Aminoglycosides [CS] CS All 66 members
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members
Polymyxin-class Antibacterial [EPC] EPC All 55 members
Polymyxins [CS] CS All 55 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
062423
Application type
ANDA · Abbreviated New Drug Application
Approval date
August 25, 1983
Sponsor
SANDOZ
Products on application
1
Submissions recorded
16
Products approved under application 062423.
Product Trade name Form Strength Ingredient Status TE Flags
062423-001 NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE SOLUTION/DROPS HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE Prescription AT

Therapeutic equivalence

Source: Orange Book
TE code
AT
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated (topical dermatological products)

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 062423.
Type No. Action Status Date Review
Supplement 28 Labeling Approved December 24, 2002 —
Supplement 26 Manufacturing (CMC) Approved December 24, 2002 —
Supplement 25 Manufacturing (CMC) Approved December 24, 2002 —
Supplement 24 Manufacturing (CMC) Approved December 24, 2002 —
Supplement 23 Manufacturing (CMC) Approved December 24, 2002 —
Supplement 27 Manufacturing (CMC) Approved December 23, 2002 —
Supplement 20 Manufacturing (CMC) Approved February 19, 1999 —
Supplement 19 Manufacturing (CMC) Approved February 2, 1999 —
Supplement 18 Manufacturing (CMC) Approved April 16, 1996 —
Supplement 17 Manufacturing (CMC) Approved March 14, 1994 —
Supplement 15 Manufacturing (CMC) Approved December 3, 1993 —
Supplement 16 Labeling Approved September 27, 1993 —
Supplement 14 Labeling Approved October 23, 1991 —
Supplement 13 Labeling Approved January 27, 1989 —
Supplement 12 Manufacturing (CMC) Approved November 8, 1988 —
Original application 1 Approved August 25, 1983 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250820). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20250820 HUMAN PRESCRIPTION DRUG · 20220801

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE For the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Therapy with this product should be limited to 10 consecutive days. The external auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator. For adults, four drops of the solution should be instilled into the affected ear 3 or 4 times daily. For infants and children, three drops are suggested because of the smaller capacity of the ear canal. The patient should lie with the affected ear upward and then the drops should be instilled. This position should be maintained for 5 minutes to facilitate penetration of the drops into the ear canal. Repeat, if necessary, for the opposite ear. If preferred, a cotton wick may be inserted into the canal and then the cotton may be saturated with the solution. This wick should be kept moist by adding further solution every 4 hours. The wick should be replaced at least once every 24 hours.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS This product is contraindicated in those individuals who have shown hypersensitivity to any of its components. This product should not be used if the external auditory canal disorder is suspected or known to be due to cutaneous viral infection (for example, herpes simplex virus or varicella zoster virus).

WARNINGS Neomycin can induce permanent sensorineural hearing loss due to cochlear damage, mainly destruction of hair cells in the organ of Corti. The risk of ototoxicity is greater with prolonged use; therefore, duration of therapy should be limited to 10 consecutive days (see PRECAUTIONS: General ). Patients being treated with eardrops containing neomycin should be under close clinical observation. Due to its acidity which may cause burning and stinging, Neomycin and Polymyxin B Sulfates and Hydrocortisone OTIC Solution should not be used in any patients with a perforated tympanic membrane. Neomycin sulfate may cause cutaneous sensitization. A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical neomycin is not known. Discontinue this product promptly if sensitization or irritation occurs. When using neomycin-containing products to control secondary infection in the chronic dermatoses, such as chronic otitis externa or stasis dermatitis, it should be borne in mind that the skin in these conditions is more liable than is normal skin to become sensitized to many substances, including neomycin. The manifestation of sensitization to neomycin is usually a low-grade reddening with swelling, dry scaling, and itching; it may be manifest simply as a failure to heal. Periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. These symptoms regress quickly on withdrawing the medication. Neomycin-containing applications should be avoided for the patient thereafter. Contains potassium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported [see Warnings ]. Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization. In one clinical study, using a 20% neomycin patch, neomycin-induced allergic skin reactions occurred in two of 2,175 (0.09%) individuals in the general population. 2 In another study, the incidence was found to be approximately 1%. 3 Skin hyperpigmentation has been reported with polymyxin B containing products. The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, and miliaria. Stinging and burning have been reported when this product has gained access to the middle ear. To report SUSPECTED ADVERSE REACTIONS, contact Sandoz Inc. at 1-800-525-8747 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION Neomycin and Polymyxin B Sulfates and Hydrocortisone OTIC Solution, USP is a sterile antibacterial and anti-inflammatory solution for otic use. Each mL contains: neomycin sulfate equivalent to 3.5 mg neomycin base, polymyxin B sulfate equivalent to 10,000 polymyxin B units, and hydrocortisone 10 mg (1%). The vehicle contains potassium metabisulfite 0.1% (added as a preservative) and the inactive ingredients glycerin, propylene glycol, hydrochloric acid, and Water for Injection. Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of Streptomyces fradiae Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 mcg of neomycin standard per mg, calculated on an anhydrous basis. The structural formulae are: Neomycin B (R 1 =H, R 2 =CH 2 NH 2 ) Neomycin C (R 1 =CH 2 NH 2 , R 2 =H) Polymyxin B sulfate is the sulfate salt of polymyxin B 1 and B 2 , which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formulae are: Hydrocortisone, 11β,17,21-trihydroxypregn-4-ene-3, 20-dione, is an anti-inflammatory hormone. Its structural formula is: neomycin polymyxin polymyxin-text hydrocortisone

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Bottle of 10 mL with sterilized dropper NDC 63187-568-10 Store at 15 ° to 25 ° C (59 ° to 77 ° F). Rx Only Also Available: Neomycin and Polymyxin B Sulfates and Hydrocortisone OTIC Suspension, USP bottle of 10 mL with sterilized dropper.

Adverse event reports

Source: openFDA FAERS
123,956
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: HYDROCORTISONE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
63187-568-10 63187-568 Proficient Rx LP 10 mL in 1 BOTTLE (63187-568-10) December 1, 2018
61314-646-10 61314-646 Sandoz Inc 1 BOTTLE in 1 CARTON (61314-646-10) / 10 mL in 1 BOTTLE March 18, 2003
63187-568 63187-568 Proficient Rx LP — March 18, 2003
61314-646 61314-646 Sandoz Inc — March 18, 2003

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.